13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001839435
Total reported value
$1.1B
$1.1B
31 檔
24.5%
As reported in its official Q4 2024 Form 13F filing, Octagon Capital Advisors LP's tracked investment portfolio stood at $1.1B with 31 total positions.
In Q4 2024, Octagon Capital Advisors LP adopted a defensive or profit-taking posture, trimming 4 positions and completely liquidating 17 holdings to manage risk exposure.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | APLSUSD | Apellis Pharmaceuticals Inc | Stock-Other | 15.79% | — | — | |
| 2 | AVBP | Arrivent Biopharma Inc | Stock-Other | 9.03% | +1.12% | +4.20% | |
| 3 | DNTH | Dianthus Therapeutics Inc | Stock-Other | 7.57% | -1.94% | +20.81% | |
| 4 | INSM | Insmed Inc | Stock-Healthcare | 6.61% | — | -15.26% | |
| 5 | 260 | Centessa Pharmaceuticals-adr | Stock-Other | 5.91% | -3.30% | EXIT | |
| 6 | VRNA | Verona Pharma PLC - Adr | Stock-Other | 4.37% | — | -68.87% | |
| 7 | NUVB | Nuvation Bio Inc | Stock-Other | 4.03% | — | -24.39% | |
| 8 | COGT | Cogent Biosciences Inc | Stock-Other | 3.55% | -1.84% | +111.72% | |
| 9 | SRRK | Scholar Rock Holding CORP | Stock-Other | 3.47% | — | — | |
| 10 | BRD1EUR | Mind Medicine Mindmed Inc | Stock-Other | 3.46% | — | — | |
| 11 | OCUL | Ocular Therapeutix Inc | Stock-Other | 3.41% | -1.14% | — | |
| 12 | TSHA | Taysha Gene Therapies Inc | Stock-Other | 2.97% | +1.55% | +128.55% | |
| 13 | VRDN | Viridian Therapeutics Inc | Stock-Other | 2.74% | — | — | |
| 14 | GOSS | Gossamer Bio Inc | Stock-Other | 2.73% | -0.17% | +99.72% | |
| 15 | DYN | Dyne Therapeutics Inc | Stock-Other | 2.59% | — | +154.26% | |
| 16 | PHVS | Pharvaris N.V. | Stock-Other | 2.45% | +0.90% | +25.39% | |
| 17 | CRBP | Corbus Pharmaceuticals Holdi | Stock-Other | 2.17% | — | — | |
| 18 | ✓ | Merus N V | Stock-Other | 2.13% | — | — | |
| 19 | ERAS | Erasca Inc | Stock-Other | 2.12% | — | — | |
| 20 | BBIO | Bridgebio Pharma Inc | Stock-Healthcare | 1.99% | — | -20.00% | |
| 21 | SNDX | Syndax Pharmaceuticals Inc | Stock-Other | 1.97% | — | — | |
| 22 | 4XC1 | Kalvista Pharmaceuticals Inc | Stock-Other | 1.91% | -3.23% | EXIT | |
| 23 | ✓ | Stock-Other | 1.31% | — | +16.84% | ||
| 24 | RGLS | Regulus Therapeutics Inc | Stock-Other | 1.26% | — | +13.72% | |
| 25 | CATX | Perspective Therapeutics Inc | Stock-Other | 1.21% | -0.37% | EXIT | |
| 26 | NGNE | Neurogene Inc | Stock-Other | 1.14% | — | +1920.00% | |
| 27 | ✓ | Allovir Inc | Stock-Other | 0.78% | — | — | |
| 28 | ATYR | Atyr Pharma Inc | Stock-Other | 0.54% | — | — | |
| 29 | ✓ | Helix Acquisition CORP Ii | Stock-Other | 0.43% | — | — | |
| 30 | ✓ | Mersana Therapeutics Inc | Stock-Other | 0.23% | — | — | |
| 31 | NUVB-WS | Nuvation Bio Inc -cw27 | Stock-Other | 0.14% | — | — |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | SRRK | Scholar Rock Holding CORP | +3.5% | NEW | New buy |
| 2 | APLSUSD | Apellis Pharmaceuticals Inc | +2.3% | — | Unchanged |
| 3 | ✓ | Merus N V | +2.1% | NEW | New buy |
| 4 | ERAS | Erasca Inc | +2.1% | NEW | New buy |
| 5 | SNDX | Syndax Pharmaceuticals Inc | +2% | NEW | New buy |
| 6 | 4XC1 | Kalvista Pharmaceuticals Inc | +1.9% | NEW | New buy |
| 7 | AVBP | Arrivent Biopharma Inc | +1.8% | +4.20% | Add |
| 8 | TSHA | Taysha Gene Therapies Inc | +1.5% | +128.55% | Add |
| 9 | COGT | Cogent Biosciences Inc | +1.4% | +111.72% | Add |
| 10 | GOSS | Gossamer Bio Inc | +1.3% | +99.72% | Add |
| 11 | DYN | Dyne Therapeutics Inc | +1.1% | +154.26% | Add |
| 12 | NGNE | Neurogene Inc | +1% | +1920.00% | Add |
| 13 | 260 | Centessa Pharmaceuticals-adr | +0.9% | +6.61% | Add |
| 14 | BRD1EUR | Mind Medicine Mindmed Inc | +0.8% | — | Unchanged |
| 15 | ✓ | Allovir Inc | +0.8% | NEW | New buy |
| 16 | ✓ | +0.8% | +16.84% | Add | |
| 17 | PHVS | Pharvaris N.V. | +0.7% | +25.39% | Add |
| 18 | ATYR | Atyr Pharma Inc | +0.5% | NEW | New buy |
| 19 | RGLS | Regulus Therapeutics Inc | +0.2% | +13.72% | Add |
| 20 | DNTH | Dianthus Therapeutics Inc | +0.1% | +20.81% | Add |
| 21 | OCUL | Ocular Therapeutix Inc | +0.1% | — | Unchanged |
| 22 | NUVB-WS | Nuvation Bio Inc -cw27 | 0% | — | Unchanged |
| 23 | ✓ | Helix Acquisition CORP Ii | 0% | — | Unchanged |
| 24 | ✓ | Mersana Therapeutics Inc | -0.1% | — | Unchanged |
| 25 | NKTX | Nkarta Inc | -0.1% | EXIT | Sold out |
| 26 | ✓ | Rapt Therapeutics Inc | -0.1% | EXIT | Sold out |
| 27 | AUTL | Autolus Therapeutics PLC | -0.1% | EXIT | Sold out |
| 28 | ✓ | -0.2% | EXIT | Sold out | |
| 29 | IPSC | Century Therapeutics Inc | -0.2% | EXIT | Sold out |
| 30 | BBIO | Bridgebio Pharma Inc | -0.2% | -20.00% | Trim |
| 31 | NUVB | Nuvation Bio Inc | -0.3% | -24.39% | Trim |
| 32 | VRDN | Viridian Therapeutics Inc | -0.3% | — | Unchanged |
| 33 | ANNX | Annexon Inc | -0.4% | EXIT | Sold out |
| 34 | BDTX | Black Diamond Therapeutics I | -0.4% | EXIT | Sold out |
| 35 | PEPG | Pepgen Inc | -0.5% | EXIT | Sold out |
| 36 | ✓ | Reneo Pharmaceuticals Inc | -0.6% | EXIT | Sold out |
| 37 | HELP | Cybin Inc | -0.7% | EXIT | Sold out |
| 38 | TNYA | Tenaya Therapeutics Inc | -0.8% | EXIT | Sold out |
| 39 | VTYXUSD | Ventyx Biosciences Inc | -0.8% | EXIT | Sold out |
| 40 | MLYS | Mineralys Therapeutics Inc | -1.1% | EXIT | Sold out |
| 41 | PRAX | Praxis Precision Medicines I | -1.2% | EXIT | Sold out |
| 42 | INSM | Insmed Inc | -1.2% | -15.26% | Trim |
| 43 | EYPT | Eyepoint Inc | -1.4% | EXIT | Sold out |
| 44 | ✓ | -1.4% | EXIT | Sold out | |
| 45 | CRBP | Corbus Pharmaceuticals Holdi | -1.4% | — | Unchanged |
| 46 | CATX | Perspective Therapeutics Inc | -1.7% | +62.05% | Add |
| 47 | VRNA | Verona Pharma PLC - Adr | -3.8% | -68.87% | Trim |
| 48 | GPCR | Structure Therapeutics Inc | -8.2% | EXIT | Sold out |
According to official SEC Form 13F filings, Octagon Capital Advisors LP reported a total U.S. public equity portfolio value of $1.1B across 31 disclosed positions in Q4 2024.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including APLSUSD, AVBP, DNTH) accounted for 24.5% of total reported equity market value during Q4 2024.
Top New Position Initiated
SRRK
市值: $21.1M
Top Position Liquidated / Trimmed
GPCR
前期市值: $52.6M
During Q4 2024, Octagon Capital Advisors LP's top holdings by market value included APLSUSD (15.8%)、AVBP (9.0%)、DNTH (7.6%). The largest single position, APLSUSD, represented 15.8% of total portfolio value.
In Q4 2024, Octagon Capital Advisors LP made 40 total portfolio adjustments, initiating 7 new buys, adding to 12 positions, trimming 4 holdings, and fully liquidating 17 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.